Full-Time

Quality Assurance Disposition Specialist

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

No salary listed

Rensselaer, NY, USA

In Person

Relocation assistance is available.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
ERP
GMP
Quality Assurance (QA)

Get referred to Curia

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Life Science or a related field is required.
  • At least 5 years of experience in quality operations and batch record reviews in GMP- and FDA-regulated drug substance or drug product manufacturing facilities is required.
  • Strong knowledge of Good Manufacturing Practices, Good Documentation Practices, and data integrity requirements is required, including current regulatory understanding and best practices such as ICH Q7 and 21 CFR Part 211.192.
  • Excellent verbal and written communication skills are required.
  • Attention to detail, self-starting ability, and the ability to work independently and proactively are required.
  • The ability to multitask is required.
  • Strong problem-solving, organizational, and critical-thinking skills are required, including familiarity with root-cause analysis.
  • The employee must pass a background check and drug screen and may be required to pass occupational health screening.
  • The employee must occasionally lift or move up to 50 pounds.
  • Personal protective equipment is required when exposed to fumes, airborne particles, or toxic or caustic chemicals.
  • Employees responsible for hazardous waste must be familiar with applicable Resource Conservation and Recovery Act training requirements and hazardous-waste handling requirements, including labeling, secondary containment, chemical compatibility, storage limits, container limits, container integrity, and proper disposal.
Responsibilities
  • Review manufacturing and cleaning batch records for conformance with Good Manufacturing Practices and Good Documentation Practices.
  • Review batch records to verify that Good Documentation Practice requirements are addressed according to site procedures.
  • Verify that yield and reconciliation calculations are accurate and within established limits.
  • Confirm that all critical process parameters have been met.
  • Review open change controls specific to the product under disposition to ensure they do not affect batch disposition.
  • Verify that deviations affecting the product lot have been identified, investigated, and approved.
  • Ensure equipment used during manufacturing was within calibration and that out-of-tolerance calibration events were investigated.
  • Confirm that all line-clearance requirements were met before manufacturing began.
  • Ensure corrections identified during batch-record review are appropriately addressed.
  • Review analytical batch records for Good Documentation Practice compliance, conformance to specifications, and completeness.
  • Perform lot disposition in the enterprise resource planning system after batch-record and disposition requirements are met according to approved site procedures.
  • Critically review documentation to ensure completeness, accuracy, and compliance with applicable batch-record requirements and standard operating procedures.
  • Escalate issues as appropriate for batches pending disposition.
  • Communicate with cross-functional departments to support on-time disposition and keep direct management informed of batch-disposition progress.
  • Perform duties under limited supervision and in accordance with standard operating procedures.
  • Collaborate with Manufacturing to resolve batch-record discrepancies or errors related to Good Documentation Practices.
  • Collaborate within the Batch Disposition team, the Quality department, Manufacturing Operations, Technical Support, Supply Chain, and Planning.
  • Move or generate hazardous waste for treatment, storage, and disposal when assigned.
  • Perform the physical duties of the role, including sitting, using hands, talking or hearing, reaching, standing, walking, climbing or balancing, and occasionally stooping, kneeling, crouching, or crawling.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.